HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN

To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer.　The present inventors have examined compounds useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a heterocyclic compound...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ISHIOKA, Hiroki, KAWAGUCHI, Kenichi, KAWAMINAMI, Eiji, IMAIZUMI, Tomoyoshi, MORIKAWA, Takahiro, INAMURA, Kohei, KURAMOTO, Kazuyuki, TAKAHASHI, Fumie, WATANABE, Hideyuki, HAMAGUCHI, Hisao, NAGASHIMA, Takeyuki, YOSHINARI, Tomohiro
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer.　The present inventors have examined compounds useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a heterocyclic compounds represented by formula (I) and formula (A) have an excellent action for inducing the degradation of G12D mutant KRAS protein and G12D mutant KRAS inhibitory activity and can be used as a therapeutic agent for pancreatic cancer, thereby completing the present invention. The heterocyclic compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.